Mysimba (Bupropion Hydrochloride, Naltrexone Hydrochloride)

The combination works by influencing two pathways in the brain. Bupropion increases the activity of norepinephrine and dopamine, stimulating appetite‑suppressing neurons in the hypothalamus. Naltrexone blocks opioid receptors that normally limit this signal, thereby enhancing the overall reduction in food intake and the reward response to eating.

The specific dose and titration schedule for Mysimba are determined by the prescribing clinician based on the individual’s medical history, body‑mass index and tolerance. Patients should follow the prescriber’s instructions and not adjust the dose without medical guidance.

Safety data for Mysimba in pregnancy and lactation are limited. It should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss alternatives with their healthcare provider.

To request Mysimba, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Mysimba is unique because it combines a norepinephrine‑dopamine reuptake inhibitor with an opioid antagonist, targeting both appetite and reward pathways. Other approved obesity agents may act solely on gastric motility, fat absorption or single neurotransmitter systems, which can result in different efficacy and side‑effect profiles.

Mysimba tablets should be stored at ambient temperature, preferably below 25 °C, in the original container to protect them from moisture and light. Keep the medication out of reach of children and do not use after the expiry date printed on the packaging.

Mysimba is taken orally as a tablet. The usual practice is to start with a low dose and gradually increase, as directed by the prescriber, to minimise side effects. Tablets should be swallowed whole with water and taken with or without food according to the clinician’s guidance.

The most serious risks include elevated blood pressure, seizures, emergence of suicidal thoughts or behaviours, severe allergic reactions, and potential liver injury. Patients should be monitored regularly for these events, and any concerning symptoms should be reported to a healthcare professional immediately.

Mysimba is contraindicated in individuals with a known hypersensitivity to bupropion, naltrexone or any tablet components, those currently taking monoamine oxidase inhibitors, patients with a seizure disorder, uncontrolled hypertension, or those who are pregnant or breastfeeding unless the prescriber determines that benefits outweigh risks.